Retatrutide vs Semaglutide vs Tirzepatide: What Sets Them Apart?
These medicines differ in hormone targets, approval status and available evidence. Here is the practical comparison without pretending that an investigational medicine is already a normal treatment option.
Educational content only. Treatment decisions must be made with a licensed healthcare professional.
GLP-1 TargetDual GLP-1 and GIPTriple Agonist ResearchApproved vs InvestigationalClinician Review Matters
The Short Version
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and GIP receptors. Retatrutide acts on GLP-1, GIP and glucagon receptors. The number of targets alone does not tell you which medicine is best, safest or most suitable for a particular person. Specific branded semaglutide and tirzepatide products are FDA-approved for defined indications. Retatrutide is not approved by any regulator and Lilly says it is legally available only through its clinical trials.
For a broader introduction, read the HealthyPA GLP-1 weight loss guide.
How Each One Works
Semaglutide
A GLP-1 receptor agonist. FDA-approved branded formulations have specific indications, including chronic weight management and type 2 diabetes.
Tirzepatide
A dual GIP and GLP-1 receptor agonist. FDA-approved branded formulations also have specific indications.
Retatrutide
An investigational triple agonist targeting GIP, GLP-1 and glucagon receptors. Its safety and effectiveness are still being evaluated.
Dosing is product-specific
Approved products have their own prescribing information. Retatrutide dosing is studied only within clinical-trial protocols.
Full Comparison
| Medication | Hormone targets | Current status | Availability | Important note |
|---|---|---|---|---|
| Semaglutide | GLP-1 | Specific branded formulations are FDA-approved for defined indications | Prescription only when clinically appropriate | Compounded preparations are not FDA-approved and are not equivalent to FDA-approved branded products. |
| Tirzepatide | GIP and GLP-1 | Specific branded formulations are FDA-approved for defined indications | Prescription only when clinically appropriate | Medication suitability depends on the approved indication, health history and clinician judgment. |
| Retatrutide | GIP, GLP-1 and glucagon | Investigational and not approved by any regulatory agency | Legally available only through Lilly clinical trials | FDA states retatrutide cannot be used in compounding under federal law. Hume Care does not offer it. |
“Semaglutide” and “tirzepatide” are active ingredients. Approval and indications apply to specific branded products and formulations, not every product advertised online.
How a Clinician Compares Available Options
Factors that may support consideration
- The medication has an approved indication relevant to the patient
- Health history and current medicines have been reviewed
- Potential benefits and risks have been discussed
- Follow-up and monitoring are available
Reasons an option may not be suitable
- Contraindications or important safety concerns
- Medication interactions or unresolved symptoms
- Pregnancy, breastfeeding or plans that affect treatment choice
- Cost, availability or a need for in-person care
- Independent clinical judgment that another approach is better
Read the separate GLP-1 eligibility guide for a clearer explanation of platform eligibility versus clinical suitability.
What Can You Explore Through Hume Care?
Hume Care is a technology and administrative platform. According to its current terms, independent Clinical Network physicians may consider FDA-approved branded GLP-1 medications or, in limited individual circumstances, compounded GLP-1 preparations. Compounded medications are not FDA-approved. Hume does not guarantee any particular medication, prescription approval or pharmacy availability.
Retatrutide is not an available Hume Care option. Eligible US adults in covered states can complete the assessment to find out whether an independent clinician considers any current option appropriate.
Affiliate link. HealthyPA may earn a commission if you proceed. US adults aged 18+ only. Availability varies by state. Assessment completion does not guarantee treatment, medication or a prescription.
Frequently Asked Questions
Is tirzepatide automatically better than semaglutide?
No. They have different mechanisms and evidence bases, but suitability depends on the person, indication, safety considerations and clinician judgment.
Does targeting more receptors automatically mean better results?
No. Receptor count alone cannot establish overall benefit, safety or suitability. Those questions require completed trials, regulatory review and individual clinical assessment.
Can I choose a specific medication through Hume Care?
You may discuss preferences, but the independent clinician determines whether treatment is appropriate. Hume does not guarantee any particular medication or prescription.
Are compounded semaglutide and tirzepatide FDA-approved?
No. FDA and Hume Care’s terms state that compounded medications are not FDA-approved and have not undergone FDA review for safety, effectiveness or manufacturing quality.
Can retatrutide be compounded?
No. FDA states that retatrutide cannot be used in compounding under federal law. Lilly says it is legally available only in its clinical trials.
Is retatrutide worth waiting for?
There is no confirmed approval or launch date. A licensed clinician can help you discuss currently approved options rather than basing a health decision on an investigational product’s future availability.
References
Sources checked 15 July 2026. Provider terms, coverage and medication availability can change.
- FDA: Wegovy (semaglutide) prescribing information
- FDA: Zepbound (tirzepatide) approval for chronic weight management
- FDA: Concerns with unapproved and compounded GLP-1 drugs
- Lilly: Current retatrutide status and legal availability
- ClinicalTrials.gov: Retatrutide Phase 3 obesity study
- Hume Care: Terms of Service